PolyPid Ltd. announced on August 12, 2025, the appointment of Dr. Nurit Tweezer-Zaks, M.D., M.B.A., as its Chief Medical Officer, effective August 18, 2025. Dr. Tweezer-Zaks will step down from PolyPid's Board of Directors, where she had served since November 2023.
Dr. Tweezer-Zaks brings extensive executive, medical, and research and development expertise to her new role. Her previous positions include Chief Executive Officer of MediCane Health Inc., Chief Medical Officer at aMOON Venture Capital Fund, and senior roles at Sanofi focusing on external innovation and life cycle management.
Her appointment is considered pivotal as PolyPid prepares for its upcoming New Drug Application (NDA) submission for D-PLEX100 and advances its pipeline, including the recently unveiled GLP-1 program. Her leadership is expected to be invaluable in guiding the company's medical affairs strategies.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.